Multiple myeloma and high cut-off haemodialysis: On the right track for better outcomes?

Background: Acute kidney injury secondary to cast nephropathy is a common complication of multiple myeloma. Extracorporeal light chain elimination by high cut-off haemodialysis has been described as an adjuvant to effective chemotherapy to limit free light chain toxicity. The purpose of this study was to evaluate the impact of high cut-off haemodialysis and bortezomib-based chemotherapy on renal function recovery and overall survival in a cohort of patients with multiple myeloma and dialysis-dependent acute kidney injury. Methods: We did a historical cohort study of patients with multiple myeloma and dialysis-dependent acute kidney injury presenting to our Centre between the 1st January 1999 and 31st March 2013. Results: Forty-six patients were included, with a median age of 68 (56-73 Y) years old. Twenty-four per cent recovered renal function. Patients submitted to high cut-off haemodialysis had a significantly higher probability of renal function recovery (OR = 11.5; 95% IC: 1.0 to 126.5). Seventy-two per cent of the patients died. The median survival rate was 20 months and overall 1-year survival rate was 58.3%. Male sex was associated with worse overall survival (HR = 4.9; 95% CI: 2.0-12.3). Renal function recovery decreased the risk of death (HR = 0.24; 95% CI: 0.07-0.80) as compared with those who remained on dialysis. The use of HCOH had no influence on the risk of death. Conclusions: Adding high cut-off haemodialysis to the novel anti-myeloma agents was independently associated to better renal outcomes in patients with multiple myeloma and dialysis-dependent acute kidney injury. However, our confidence in these results is hampered by the observational nature of the study, and by the small sample size and imprecise estimates of effect. Randomized controlled trials addressing this issue are urgently needed

Saved in:
Bibliographic Details
Main Authors: Chuva,Teresa, Maximino,José, Barbosa,Joselina, Santos,Paulo, Silva,Sandra, Paiva,Ana, Baldaia,Jorge, Santos,Teresa, Loureiro,Alfredo
Format: Digital revista
Language:English
Published: Sociedade Portuguesa de Nefrologia 2016
Online Access:http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692016000400003
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0872-01692016000400003
record_format ojs
spelling oai:scielo:S0872-016920160004000032017-03-07Multiple myeloma and high cut-off haemodialysis: On the right track for better outcomes?Chuva,TeresaMaximino,JoséBarbosa,JoselinaSantos,PauloSilva,SandraPaiva,AnaBaldaia,JorgeSantos,TeresaLoureiro,Alfredo Acute kidney injury chemotherapy haemodialysis multiple myeloma Background: Acute kidney injury secondary to cast nephropathy is a common complication of multiple myeloma. Extracorporeal light chain elimination by high cut-off haemodialysis has been described as an adjuvant to effective chemotherapy to limit free light chain toxicity. The purpose of this study was to evaluate the impact of high cut-off haemodialysis and bortezomib-based chemotherapy on renal function recovery and overall survival in a cohort of patients with multiple myeloma and dialysis-dependent acute kidney injury. Methods: We did a historical cohort study of patients with multiple myeloma and dialysis-dependent acute kidney injury presenting to our Centre between the 1st January 1999 and 31st March 2013. Results: Forty-six patients were included, with a median age of 68 (56-73 Y) years old. Twenty-four per cent recovered renal function. Patients submitted to high cut-off haemodialysis had a significantly higher probability of renal function recovery (OR = 11.5; 95% IC: 1.0 to 126.5). Seventy-two per cent of the patients died. The median survival rate was 20 months and overall 1-year survival rate was 58.3%. Male sex was associated with worse overall survival (HR = 4.9; 95% CI: 2.0-12.3). Renal function recovery decreased the risk of death (HR = 0.24; 95% CI: 0.07-0.80) as compared with those who remained on dialysis. The use of HCOH had no influence on the risk of death. Conclusions: Adding high cut-off haemodialysis to the novel anti-myeloma agents was independently associated to better renal outcomes in patients with multiple myeloma and dialysis-dependent acute kidney injury. However, our confidence in these results is hampered by the observational nature of the study, and by the small sample size and imprecise estimates of effect. Randomized controlled trials addressing this issue are urgently neededinfo:eu-repo/semantics/openAccessSociedade Portuguesa de NefrologiaPortuguese Journal of Nephrology & Hypertension v.30 n.4 20162016-12-01info:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692016000400003en
institution SCIELO
collection OJS
country Portugal
countrycode PT
component Revista
access En linea
databasecode rev-scielo-pt
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Chuva,Teresa
Maximino,José
Barbosa,Joselina
Santos,Paulo
Silva,Sandra
Paiva,Ana
Baldaia,Jorge
Santos,Teresa
Loureiro,Alfredo
spellingShingle Chuva,Teresa
Maximino,José
Barbosa,Joselina
Santos,Paulo
Silva,Sandra
Paiva,Ana
Baldaia,Jorge
Santos,Teresa
Loureiro,Alfredo
Multiple myeloma and high cut-off haemodialysis: On the right track for better outcomes?
author_facet Chuva,Teresa
Maximino,José
Barbosa,Joselina
Santos,Paulo
Silva,Sandra
Paiva,Ana
Baldaia,Jorge
Santos,Teresa
Loureiro,Alfredo
author_sort Chuva,Teresa
title Multiple myeloma and high cut-off haemodialysis: On the right track for better outcomes?
title_short Multiple myeloma and high cut-off haemodialysis: On the right track for better outcomes?
title_full Multiple myeloma and high cut-off haemodialysis: On the right track for better outcomes?
title_fullStr Multiple myeloma and high cut-off haemodialysis: On the right track for better outcomes?
title_full_unstemmed Multiple myeloma and high cut-off haemodialysis: On the right track for better outcomes?
title_sort multiple myeloma and high cut-off haemodialysis: on the right track for better outcomes?
description Background: Acute kidney injury secondary to cast nephropathy is a common complication of multiple myeloma. Extracorporeal light chain elimination by high cut-off haemodialysis has been described as an adjuvant to effective chemotherapy to limit free light chain toxicity. The purpose of this study was to evaluate the impact of high cut-off haemodialysis and bortezomib-based chemotherapy on renal function recovery and overall survival in a cohort of patients with multiple myeloma and dialysis-dependent acute kidney injury. Methods: We did a historical cohort study of patients with multiple myeloma and dialysis-dependent acute kidney injury presenting to our Centre between the 1st January 1999 and 31st March 2013. Results: Forty-six patients were included, with a median age of 68 (56-73 Y) years old. Twenty-four per cent recovered renal function. Patients submitted to high cut-off haemodialysis had a significantly higher probability of renal function recovery (OR = 11.5; 95% IC: 1.0 to 126.5). Seventy-two per cent of the patients died. The median survival rate was 20 months and overall 1-year survival rate was 58.3%. Male sex was associated with worse overall survival (HR = 4.9; 95% CI: 2.0-12.3). Renal function recovery decreased the risk of death (HR = 0.24; 95% CI: 0.07-0.80) as compared with those who remained on dialysis. The use of HCOH had no influence on the risk of death. Conclusions: Adding high cut-off haemodialysis to the novel anti-myeloma agents was independently associated to better renal outcomes in patients with multiple myeloma and dialysis-dependent acute kidney injury. However, our confidence in these results is hampered by the observational nature of the study, and by the small sample size and imprecise estimates of effect. Randomized controlled trials addressing this issue are urgently needed
publisher Sociedade Portuguesa de Nefrologia
publishDate 2016
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692016000400003
work_keys_str_mv AT chuvateresa multiplemyelomaandhighcutoffhaemodialysisontherighttrackforbetteroutcomes
AT maximinojose multiplemyelomaandhighcutoffhaemodialysisontherighttrackforbetteroutcomes
AT barbosajoselina multiplemyelomaandhighcutoffhaemodialysisontherighttrackforbetteroutcomes
AT santospaulo multiplemyelomaandhighcutoffhaemodialysisontherighttrackforbetteroutcomes
AT silvasandra multiplemyelomaandhighcutoffhaemodialysisontherighttrackforbetteroutcomes
AT paivaana multiplemyelomaandhighcutoffhaemodialysisontherighttrackforbetteroutcomes
AT baldaiajorge multiplemyelomaandhighcutoffhaemodialysisontherighttrackforbetteroutcomes
AT santosteresa multiplemyelomaandhighcutoffhaemodialysisontherighttrackforbetteroutcomes
AT loureiroalfredo multiplemyelomaandhighcutoffhaemodialysisontherighttrackforbetteroutcomes
_version_ 1756001682521587712